GIORGIO, ELEONORA
GIORGIO, ELEONORA
Dipartimento di Scienze Farmacologiche e Biomolecolari
Dysfunctional HDL as a therapeutic target for atherosclerosis prevention
2019 A. Ossoli, C. Pavanello, E. Giorgio, L. Calabresi, M. Gomaraschi
HDL-mediated reduction of cholesterol content inhibits the proliferation of prostate cancer cells induced by LDL : Role of ABCA1 and proteasome inhibition
2022 A. Ossoli, E. Giorgio, F. Cetti, M. Ruscica, C. Rabacchi, P. Tarugi, P. Parini, M. Pedrelli, M. Gomaraschi
High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation
2018 M. Ruscica, M. Botta, N. Ferri, E. Giorgio, C. Macchi, G. Franceschini, P. Magni, L. Calabresi, M. Gomaraschi
LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters
2020 L. Arnaboldi, A.F. Ossoli, E. Giorgio, L. Pisciotta, T. Lucchi, L. Grigore, C. Pavanello, A.C. Granata, A. Pasta, B. Arosio, D. Azzolino, A. Baragetti, S. Castelnuovo, A. Corsini, A.L. Catapano, L. Calabresi, M. Gomaraschi
Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes : evidence in NAFLD patients and cell cultures
2019 M. Gomaraschi, A.L. Fracanzani, P. Dongiovanni, C. Pavanello, E. Giorgio, L. Da Dalt, G.D. Norata, L. Calabresi, D. Consonni, R. Lombardi, A. Branchi, S. Fargion
THE ANTITUMORAL ROLE OF HDL: IN VITRO STUDIES ON PROSTATE CANCER CELL LINES
2021 E. Giorgio
Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients
2019 C. Pavanello, A. Baragetti, A. Branchi, L. Grigore, S. Castelnuovo, E. Giorgio, A.L. Catapano, L. Calabresi, M. Gomaraschi